Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis

Area of Science:

• Immunology
• Neuroscience
• Genetics

Background:

• Experimental autoimmune encephalomyelitis (EAE) is a model for multiple sclerosis.
• Studies show increased CNS injury in Daf1-deficient mice, suggesting a protective role for DAF.
• DAF (Decay Accelerating Factor) is a complement regulatory protein.

Purpose of the Study:

• To investigate the therapeutic potential of elevated DAF levels in an EAE model.
• To determine if increased DAF expression ameliorates autoimmune neuroinflammation.

Main Methods:

• Generated Daf1 transgenic (Tg) mice with enhanced cell surface DAF expression.
• Assessed C3b uptake by erythrocytes.
• Co-cultured bone marrow-derived dendritic cells (BM-DCs) with T cells.
• Induced EAE in WT and Daf1 Tg mice using MOG(35-55) peptide.
• Performed histological analysis of spinal cords and measured T cell responses.

Main Results:

• Daf1 Tg erythrocytes showed reduced C3b uptake.
• Daf1 Tg BM-DCs produced less C5a and C3a, leading to a reduced T cell response.
• Daf1 Tg mice exhibited delayed EAE onset and decreased clinical scores.
• Histology revealed reduced inflammation and demyelination in Daf1 Tg mice.
• Decreased MOG(35-55) specific Th1 and Th17 responses were observed in Daf1 Tg mice.

Conclusions:

• DAF suppresses autoreactive T cell responses in EAE.
• Augmenting DAF expression may be a viable therapeutic strategy for multiple sclerosis and other T cell-mediated diseases.